{"schema_version":"1.0","type":"article","title":"Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?","url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.md","lang":"en","date":"2026-06-02","publish_at":"2026-06-02T10:30:00+08:00","updated_at":"2026-06-02","category":"商業分析系列","topic":"臨床與 CMC","tags":["Clinical and CMC","CNS","Big Pharma","Capital markets","Biotech business analysis","Drug development"],"summary":"Biogen's BIIB080 tau program reflects a broader Alzheimer's reset: the field is no longer only asking whether amyloid matters, but whether tau biology can produce measurable disease-modifying benefit.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-02）。Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?。https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-02-biogen-alzheimers-tau-biib080-strategy.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}